Halozyme Therapeutics Inc.
HALO - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$14.87B
Close$
$98.59
24.4% downside
Current Fair Value
24.4% downsideOvervalued by 24.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $14.87 Billion |
|---|---|
| Enterprise Value | $16.86 Billion |
| Earnings per Share | $2.64 |
| Beta | 0.88 |
| Outstanding Shares | 117,274,000 |
Return
| Return on Equity | 288.13% |
|---|---|
| Return on Assets | 16.05% |
| Return on Invested Capital | 42.54% |
Valuation & Multiples
| P/E Ratio | 37.19 |
|---|---|
| PEG | 94.86 |
| Price to Sales | 9.31 |
| Price to Book Ratio | 130.34 |
| Enterprise Value to Revenue | 10.13 |
| Enterprise Value to EBIT | 17.75 |
| Enterprise Value to Net Income | 40 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 14.95 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 2, 2026
EPS Estimate
$2.30
Consensus analyst estimateRevenue Estimate
$490.85 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 61.67% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | 15,000▼ 94.60% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 7.78%▼ 97.68% |
|---|---|
| Total Invested | $1.00B▼ 89.71% |
| Investors Holding | 250▼ 440.00% |
About Halozyme Therapeutics Inc.
423 employees
CEO: Helen Torley
Halozyme Therapeutics, Inc., a biopharmaceutical technology company, was established in 1998 and is based in San Diego, California. The company's operations span globally, covering markets in the United States, Switzerland, Ireland, Belg...